XACT Robotics has received US Food and Drug Administration (FDA) clearance for a modification to its XACT ACE ® Robotic System, which is designed to support robotic insertion and steering of ablation probes during ablation clinical procedures. This clearance expands the company’s indication for CT-guided percutaneous procedures with multiple clinical cases performed to date in numerous medical centers.

The comprehensive XACT ACE® is the only technology that consolidates image-based procedure planning and real time monitoring with hands free precise robotic insertion and non-linear steering. Using the XACT ACE® Robotic System for ablation probe insertion and steering, health systems can save time with quick and precise probe placement, adding to the overall procedure proficiency and success. The proprietary robotic insertion and non-linear steering delivers instruments to a desired target in the body—overcoming the size, depth, movement, or obstructions that may be in the path. The system has been proven to achieve unparalleled 1.7mm tip to target average accuracy upon first insertion, with a less than 8.5-minute average skin to target time. This has the potential to enhance a user’s ability to provide more timely and accurate diagnoses and treatment for patients, helping to reduce the “watchful waiting” period and improve outcomes. Read more here.